Abstract
Based on our earlier observation that deletion of chromosomal region 6q22-23 correlated with shorter survival of primary central nervous system lymphoma (PCNSL) patients (Cady et al, 2008) the overall goal of this study was to further refine the biomarker potential of 6q22-23. We now describe the correlation of its deletion with the overall survival (OS) of patients enrolled on three consecutive North Central Cancer Treatment Group (NCCTG) Phase II clinical trials for newly diagnosed PCNSL, 867252 (O’Neill et al, 1999), 937351 (Laack et al, in press), and 967351 (Laack et al, 2006). Formalin-fixed paraffin embedded blocks (FFPE) from patients enrolled in these three trials were retrieved from the Mayo Clinic Tumor Registry and the Biospecimen Repositories of the 30 participating trial sites (Mayo Foundation Institutional Review Board approval 08-001933). Interphase FISH was performed on thin sections of the FFPE tumour samples following our previously described method (Cady et al, 2008). Survival data were analysed for all patients, with OS being calculated from the date of tissue diagnosis to date of death or last contact. Survival curves were estimated using the Kaplan– Meier method and comparisons were made using the log rank test.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.